Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Sweat Analysis
Interventions: Gx sweat patch, Reference sweat patch; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Pancreatic Neoplasm, Peutz-Jeghers Syndrome
Interventions: Biopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Contact Dermatitis
Interventions: AI algorithm to evaluate photographs of skin test patch regions, Allergen Patch; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Overweight and/or Obesity
Interventions: VX-201, semaglutide SC; Combination Product · Drug
Lead sponsor: Terrestrial Bio, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Smoking Cessation
Interventions: Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8,144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more

Conditions: In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Interventions: Sirolimus Drug Coated Balloon, Plan balloon Angioplasty (POBA); Device
Lead sponsor: Concept Medical Inc.; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 27
States / cities: Birmingham, Alabama • Gilbert, Arizona • Los Angeles, California + 21 more

Conditions: External Genital Warts
Interventions: Sinecatechins 15% Ointment, Cryotherapy alone; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatic Cyst
Interventions: 1). EUS-FNA plus MFB, 2). EUS-FNA Alone; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Irvine, California • Aurora, Colorado • Houston, Texas

Conditions: Metastatic Breast Cancer, Brain Metastases
Interventions: Nivolumab, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Barrett's Esophagus
Interventions: Proflavine, high resolution imaging; Drug
Lead sponsor: Anandasabapathy, Sharmila, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Paroxysmal Atrial Fibrillation
Interventions: Radiofrequency Ablation; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Burlingame, California • Indianapolis, Indiana • Tupelo, Mississippi + 1 more

Conditions: Venous Stenosis, Venous Occlusion
Interventions: Merit WRAPSODY Endovascular Stent Graft, PTA; Device
Lead sponsor: Merit Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 33
States / cities: Tempe, Arizona • Tucson, Arizona • Orange, California + 26 more

Conditions: Pancreatic Cancer
Interventions: Talimogene laherparepvec; Drug
Lead sponsor: Karie D. Runcie, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease
Interventions: PROMUS Element Plus, SYNERGY; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 69
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 18
States / cities: Little Rock, Arkansas • Fountain Valley, California • Fremont, California + 15 more

Conditions: Choroidal Melanoma, Indeterminate Lesions
Interventions: Observational; Other
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 10
States / cities: Sacramento, California • Ann Arbor, Michigan • Rochester, Minnesota + 7 more

Conditions: Breast Cancer, Breast Abnormalities, Breast Lesion, Breast Asymmetry
Interventions: Wearable Ultrasound Patch; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Oral Cavity Neoplasm
Interventions: High-Resolution Microendoscopy, Multispectral Imaging, Proflavine; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuritis, Radiofrequency Ablation
Interventions: Dexamethasone 4 mg/ml, Normal saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Cord Injuries, Tendinopathy, Rotator Cuff Tears, Shoulder Pain
Interventions: Lipogems, Dexamethasone; Device · Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Laboratory Biomarker Analysis, Radiation Therapy; Other · Radiation
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: Buffalo, New York • Cheektowaga, New York

Conditions: HIV
Interventions: Digital Health Feedback System; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: San Diego, California

Conditions: Eyelid Tumor, Eyelid Bump, Eyelid Deformity, Eyelid Abscess, Eyelid Boil, Eyelid Papilloma, Anesthesia, Local, Ophthalmology
Interventions: 0.9% Bacteriostatic Local Anesthetic Injection, 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection, Eyelid Lesion Removal; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 110 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma
Interventions: Infliximab, Vedolizumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

NBA G-League Sweat Testing Study: Validity of the Gx Sweat Patch in Measuring Sweating Rate and Sweat Chloride Concentration During On-court Training With Basketball Players

Cancer of the Pancreas Screening Study (CAPS 3)

DermAI to Evaluate Human Factor of Testing

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment

Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma

LSI (Lesion Index) Workflow Observational Study

The Merit WRAPSODY AV Access Efficacy Study (WAVE)

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

Wearable Ultrasound Patch for Breast Imaging

Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery

Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation

Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy

Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma